Eligibility for Icosapent Ethyl in a French Population of Coronary Outpatients With Type 2 Diabetes

Abstract

IntroductionWe determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD).Material and methodsProspective patients with type 2 diabetes and CAD were included from 03/2019 to 12/2020.Results574 patients were included; mean age 71 years, 81% males, with a high prevalence of other risk factors (81% hypertension). Mean LDL-cholesterol was 85 mg/dL, mean HbA1c 7.1%, mean triglycerides 148 mg/dL; 82% received statins. Based on National Lipid Association criteria, 31% would be eligible for EPA.ConclusionsIn this contemporary survey in consecutive, unselected CAD patients in daily practice, almost a third would be potentially eligible for EPA.